Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Vandetanib to preparation of targeted EphB4 anti-tumor drug

An anti-tumor drug, the technology of vandetanib, applied in the field of medicine, can solve the problem that there is no report on the application of vandetanib in anti-leukemic tumors, and achieve the effect of inhibiting the activity of EphB4 kinase

Inactive Publication Date: 2018-11-13
XI AN JIAOTONG UNIV
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] There are no reports on the application of vandetanib against leukemia and tumors targeting EphB4

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Vandetanib to preparation of targeted EphB4 anti-tumor drug
  • Application of Vandetanib to preparation of targeted EphB4 anti-tumor drug
  • Application of Vandetanib to preparation of targeted EphB4 anti-tumor drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Determination of EphB4 expression by Western blotting: Western blotting was used to investigate the expression levels of EphB4 in three different types of leukemia cells. When the cells were in the exponential growth phase, the cells were lysed with RIPA cell lysate for 30 min, and the cell lysate was centrifuged at 12,000 g, 10 min, and 4° C. to precipitate the cells. Aspirate the supernatant and add a certain amount of 5×loading buffer, heat and boil for 5 minutes to denature the protein, mark it, and store it at -20°C for later use. Load the processed protein sample on the prepared 10% SDS-PAGE, add 1× electrophoresis buffer, turn on the power, and maintain a steady voltage of 120mV for sample separation. The separated samples were purposely cut and transferred to the membrane using a steady flow of 120mA. After the membrane transfer, the PVDF membrane was placed in skimmed milk powder blocking solution for blocking for 2 h. The EphB4 primary antibody was then incu...

Embodiment 2

[0031] Kinase assay to investigate the effect of vandetanib on EphB4 kinase activity: the homogeneous time-resolved fluorescence (HTRF) method was used to detect the effect of the drug on inhibiting the phosphorylation of EphB4 kinase. Add 2 μL of EphB4 kinase and 2 μL of substrate to the 384-well plate, then add 4 μL of vandetanib at different concentrations, and finally add 2 μL of ATP to the 384-well plate, and use a shaker to mix the reaction system evenly. Place the 384-well plate in a 37°C oven for incubation. After reacting for 30 minutes, add Eu 3+ -TK-antibody working solution and streptavidin-XL665 each 5μL into a 384-well plate to terminate the reaction. After reacting at room temperature for 1 h, the 384-well plate was put into a multi-functional microplate reader for detection. The detection conditions were as follows: 615nm was selected as the excitation wavelength, and 665nm was selected as the emission wavelength. see image 3 , the results showed that vande...

Embodiment 3

[0033] SPR experiment confirms the target: install an NTA chip in the OpenSPRTM instrument, and then pump the PBS buffer at the maximum flow rate. After reaching the signal baseline, inject 80% IPA (isopropanol) from the sample port, turn the control valve to inject, run for 10s and return to load to remove air bubbles, after reaching the baseline, rinse the sample loop with buffer, and use air emptying. After the signal reaches baseline, adjust the buffer flow rate to 20 μL / min. Introduce 250 μL of imidazole solution into the injection port and inject to initialize the sensor surface, initialize 2-3 times until the curve after injection is consistent. Introduce 250 μL of 40 mM NiCl 2 to the injection port and inject, through the Ni 2+The ions charge the NTA, and the surface is now ready to be functionalized with his-tag ligands. Prepare the His-tag ligand EphB4-1 (50 μg / mL) dissolved in 250 μL running buffer, inject it into the sample well, and interact for at least 5 min...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of Vandetanib to preparation of a targeted EphB4 anti-tumor drug, and belongs to the technical field of medicines. Experiments verify the application of the Vandetanib, and a molecular docking method, an SPR (surface plasmon resonance) method and MST (modulated scatterer technique) experiment results indicate that the Vandetanib can interact with EphB4. EphB4kinase experiments display that the Vandetanib can obviously inhibit EphB4 kinase activity. Proliferation of leukemic cells K562, JLTRG and H9 is remarkably inhibited. Besides, the Vandetanib remarkably inhibits expression of signal molecules p-PI3K p85 / p55 and PI3K p85 at the downstream of the EphB4, and the phosphorylation level of MEK (methyl ethyl ketone) and ERK (extracellular signal-regulated kinase) is reduced. Therefore, the experiment results sufficiently support the application of the Vandetanib to an anti-leukemia drug and the targeted EphB4 anti-tumor drug.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to the application of vandetanib in the preparation of antitumor drugs targeting EphB4. Background technique [0002] Leukemia is a common malignant tumor of the blood system and one of the top ten high-incidence malignant tumors in my country. The incidence of leukemia in various regions of China ranks sixth among various tumors. Leukemia is an abnormal clonal disease of hematopoietic stem cells with high heterogeneity. Clonal leukemia cells proliferate and accumulate in bone marrow and other hematopoietic tissues due to mechanisms such as uncontrolled proliferation, differentiation disorder, and apoptosis inhibition, and infiltrate other non-hematopoietic tissues and organs, while inhibiting normal hematopoietic function. According to the priority of onset, it can be divided into acute and chronic leukemia. Clinically, leukemia is often divided into lymphocytic leuk...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/517A61P35/00A61P35/02
CPCA61K31/517A61P35/00A61P35/02
Inventor 张彦民马维娜朱曼代秉玲张东东崔宇鑫龚政艳杨柳
Owner XI AN JIAOTONG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com